
zzso adult patients with solid tumors were treated with oral zzso a new zzso zzso active against human breast cancer after intravenous zzso The drug was given orally on 3 consecutive days every 4 weeks at doses ranging from 50 to 175 zzso zzso and zzso zzso was the zzso zzso At doses from 50 to 150 zzso zzso side effects of oral zzso were zzso and mild and consisted of zzso and vomiting (1 zzso zzso (2 zzso zzso (2 zzso and liver function test abnormalities (3 zzso The only patient treated at a daily dose of 175 zzso developed grade IV zzso with fever and gastrointestinal zzso This was followed by heart zzso and the patient died from zzso organ zzso A dose of 150 zzso for 3 consecutive days is recommended for phase II trials with oral zzso 

